medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2012, Number 6

<< Back Next >>

Salud Mental 2012; 35 (6)

Uso de marcadores bioquímicos para valoración de riesgo de crisis convulsivas en el síndrome de supresión etílica

Melchor LA, Díaz MLR, Moreno J

Language: Spanish
References: 41
Page: 499-504
PDF size: 102.84 Kb.


ABSTRACT

Withdrawal signs and symptoms are frequently minor but can develop into a severe, even fatal, condition. Clinical manifestations of the AWS begin as soon as the alcohol consumption is interrupted or diminished after a long period of ingestion of great quantities of alcohol. The clinical manifestations include symptoms of autonomic hyperactivity, like sweating, tachycardia over 100 bpm, tremor, insomnia, nausea or vomiting, transitive visual, tactile, or hearing hallucinations, or even illusions, psychomotor agitation, anxiety and epileptic crisis.
Objective: Our aim is to assess the usefulness of several biochemical markers and the risk of seizures associated with alcohol withdrawal.
Methods: This study included 52 inpatients which were assessed with the Ciwa- Ar scale in order to determine the severity of the withdrawal. They were assessed too with the AUDIT scale to determine the risk and abuse of the intake of alcohol. We also obtained a blood sample to determine the levels of several biomarkers (AST, ALT, GGT, FA, HOMOCISTEINE, and MCV). We compared the two groups (patients with seizures vs. patients without seizures). Student T and Mann Whitney´s U tests, and ROC curves were applied.
Results: We observed a statistical difference between the groups in the levels of alkaline phosphatase. The levels were higher in patients without seizures (148.8 ± 69.58UI) compared with the patients with seizures (113 ± 55.1UI). No differences were observed in other groups.
Conclusion: The patients with higher levels of alkaline phosphatase had major risk of seizures. There were no elevations in the serum level of homocisteine in both groups.



REFERENCES

  1. Lozano Nuevo JJ, Hernández Gaeta D. Concentraciones séricas de fosfato como factor implicado en la duración y gravedad del síndrome de supresión etílica. Med Int Mex 2004;20(1):183-190.

  2. Rathlev NK, Ulrich AS, Delanty N, D’Onofrio G. Alcohol-related seizures. J Emerg Med 2006;31(2):157-163.

  3. Addolorato G, Leggio L, Agabio R, Colombo G et al. A new drug for the treatment of alcohol dependence. Int J Clinical Practice 2006;60(8): 1003-1008.

  4. Medina-Mora M. SSA, INEGI, INPRMF, INSP; Encuesta Nacional de Adicciones de 2008 (ENA 2008). México; 2009.

  5. Addolorato G. Leggio L, Abenavoli L, DeLorenzi G, Parente A et al. Suppression of alcohol delirium tremens by Baclofen administration: A case report. Clinical Neuropharmacology 2003;26(5):258-262.

  6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington: 1994; pp:198-199.

  7. Bar K-J, Boettger MK, Neubauer R, Groteluschen M et al. Voss, Andreas heart rate variability and sympathetic skin response in male patients suffering from acute alcohol withdrawal syndrome. Alcoholism Clinical Experimental Research 2006;30(9):1592-1598.

  8. González LP, Veatc LM, Tichu MK et al. Alcohol withdrawal and kindling: mechanisms and implications for treatment. Alcohol Clin Expres 2001;25:1975-2015.

  9. Hannuksela ML, Liisanantti MK, Nissinen AE, Savolainen MJ. Biochemical markers of alcoholism. Clin Chem Lab Med 2007;45(8):953- 961.

  10. Salaspuro M. Use of enzymes for the diagnosis of alcohol-related organ damage. Enzyme 1987;37(1-2):87-107.

  11. Ceccanti M, Sasso GF, Nocente R, Balducci G et al. Hypertension in early alcohol withdrawal in chronic alcoholics. Alcohol Alcoholism

  12. Dolman JM, Hawkes ND. Combining the audit questionnaire and biochemical markers to assess alcohol use and risk of alcohol withdrawal in medical inpatients. Alcohol Alcoholism 2005;40(6):515-519.

  13. Ferreira González L. Escala CIWA-Ar (Clinical Institute Withdrawal Assesment for Alcohol) Evaluación del Síndrome de Abstinencia Alcohólica; Medicina Interna. CHU Juan Canalejo. A Coruña.

  14. Foy A, March S, Drinkwater V. Use of an objective clinical scale in the assessment and management of alcohol withdrawal in a large general hospital. Alcohol Clin Exp Res 1988;12(3):360-364.

  15. Hecksel KA, Bostwick J, Jaeger T, Cha SS. Inappropriate use of symptom-triggered therapy for alcohol withdrawal in the general hospital. Mayo Clinic Proceedings 2008;83(3):274-279.

  16. Huang M-Ch, Chen Ch-H, Chen Ch-H, Liu Sh-Ch et al. Alterations of serum brain-derived neurotrophic factor levels in early alcohol withdrawal. Alcohol Alcoholism 2008;43(3):241-245.

  17. Holbrook A, Pharm D, Crowther R, Lotter A et al. Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ Canadian Medical Association J 1999;160(5):649-655.

  18. Bleich S, Bayerlein K, Hillemacher T, Degner D et al. An assessment of the potential value of elevated homocysteine in predicting alcoholwithdrawal seizures. Epilepsia 2006;47(5):934-938.

  19. Horwitz RI, Gottlieb LD, Kraus ML. The efficacy of atenolol in the outpatient management of the alcohol withdrawal syndrome: results of a randomized clinical trial. Arch Intern Med 1989;149:1089-1093.

  20. Hollbrook A, Crowther R, Lotter A et al. Diagnosis and management of acute alcohol withdrawal. CMAJ 1999;160(5):675-680.

  21. Jennings-Ingle S. BSN Sobering up to alcohol withdrawal syndrome. LPN 2007;3(5):40-48.

  22. Reoux J, Miller K. Routine Hospital Alcohol Detoxification Practice Compared to Symtom Triggered Management with an Objective Withdrawal Scale (CIWA-Ar). American J Addictions 2000;9: 135-144.

  23. Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY et al. Antiglutamatergic Strategies for Ethanol Detoxification: Comparison with placebo and diazepam. Alcoholism Clinical Experimental Research 2007;31(4):604-611.

  24. McKeon A, Frye MA, Delanty N. The alcohol withdrawal syndrome. J Neurology Neurosurgery Psychiatry 2008;79(8):854-862.

  25. Pittman B, Gueorguieva R, Krupitsky E, Rudenko AA et al. Multidimensionality of the alcohol withdrawal symptom checklist: A factor analysis of the alcohol withdrawal symptom checklist and CIWA-Ar. Alcoholism Clinical Experimental Research 2007;31(4):612-618.

  26. Saitz R, O´Malley S. Pharmacotherapies for alcohol abuse. Withdrawal and treatment. Med Clin North Am 1997;81:881-907.

  27. Saunders JB, Janca A. Delirium tremens: its etiology, natural history and treatment. Curr Opinion Psychiatry 2000;13:629-633.

  28. Shaw et al. Development of optimal treatment tactics for alcohol withdrawal. Assessment and effectiveness of supportive care. J Clin Psychopharmacol 1981;1:382-387.

  29. Stuppaeck CH, Barnas C, Falk M, Guenther V et al. Assessment of the alcohol withdrawal syndrome-validity and reliability of the translated and modified Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-A).] Addiction 1994;89(10):1287-1292.

  30. Sullivan JT, Sykora K, Schneiderman J et al. Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). Br J Addict 1989;84:1353-1357.

  31. Wetterling T, Kanitz RD, Veltrup C, Driessen M. Clinical predictors of alcohol withdrawal delirium. Alcohol Clin Exp Res. 1994;18(5):1100- 1102.

  32. No se muestran los autores. Alcohol withdrawal syndrome: how to predict, prevent, diagnose and treat it. Prescrire Int 2007;16(87):24-31.

  33. Kraemer KL, Mayo-Smith MF, Calkins DR. Independent clinical correlates of severe alcohol withdrawal. Substance Abuse 2003;24(4):197- 209.

  34. Das SK, Dhanya L, Vasudevan DM. Biomarkers of alcoholism: an updated review Scand J Clin Lab Invest 2008;68(2):81-92.

  35. Sharpe PC. Biochemical detection and monitoring of alcohol abuse and abstinence. Ann Clin Biochem 2002;39(Pt 4):41.

  36. Hillemacher T, Frieling H, Bayerlein K, Wilhelm J et al. Biological markers to predict previous alcohol withdrawal seizures: a risk assessment J Neural Transm 2007;114(2):151-154.

  37. Sakutata H, Suzuki T, Yasuda H, Ito T. Beverage-specific effects of ethanol consumption on its biological markers Clin Chem Lab Med 2008;46(5):699-702.

  38. Onni Niemelä Biomarkers in alcoholism Clinica Chimica Acta 2006;364:167–171.

  39. Lech Chrostek A, Bogdan Cylwik A, Maciej Szmitkowski A, Walenty Korcz. The diagnostic accuracy of carbohydrate-deficient transferrin, sialic acid and commonly used markers of alcohol abuse during abstinence Clinica Chimica Acta 2006;364:167–171.

  40. Sáiz PA, G-Portilla MP, Paredes MAB, Bascarán MT. Instrumentos de evaluación en alcoholismo. Adicciones 2002;14(Supl. 1).

  41. Tilman W, Rolf-Deter K, Bettina B. A new rating scale for the assessment of the alcohol-withdrawal syndrome (AWS scale). Alcohol Alcoholism 1997;32(6):753-760.




2020     |     www.medigraphic.com